The Medical College of Wisconsin (MCW) has received a two-year, $153,000 grant from the National Institute of Health’s National Cancer Institute to evaluate a potential new pathway for inhibiting the growth of cancer cells. This new pathway could lead to new diagnostic and therapeutic tools in treating malignancies.
Andrey Sorokin, Ph.D., professor of medicine in the division of nephrology at MCW, is the primary investigator of the grant.
COX-2 is an enzyme that plays a critical role in the development and spread of cancers. Currently, COX-2 inhibitors are utilized as treatments in prostate cancers and some other types of cancers. However, Dr. Sorokin’s research indicates there may be a more effective target to turn “off” the switch that allows the cancer cells to continue to grow.
In this project, Dr. Sorokin and his team will evaluate COX-2 regulation by a type of enzymes called kinases that modifies proteins by adding a phosphate group. A specific kinase called Fyn has been linked to cancer progression and will be evaluated as a novel regulator of COX-2. The project will enhance our understanding of the signaling mechanisms at a cellular level that cause cancer progression, and could provide new diagnostic tools and offer novel therapeutic targets to treat prostate cancer.
This project is supported by NIH grant R03CA182114-01A1.
Your link to the biggest stories in the suburbs delivered Thursday mornings.
Enter your e-mail address above and click "Sign Up Now!" to begin receiving your e-mail newsletter Get the Newsletter!
- How light therapy heals wounds
- Holiday Happenings on Vliet Street!!
- Holiday Folk Fair Producer to Help Fight Ebola
- CIGARMKE - KNOW YOUR LEAF - PART 1
- CIGARMKE LET'S GET LIT - FALL 2014 ON NOV. 8TH
- Local Businesses in Three Communities Band Together to Fight Hunger, Support New Berlin Food Pantry
- Our TreASures … Our Heart
- Cardiovascular and cancer researcher elected Fellow of the American Heart Association
- Mini Book Sale December 8th
- Parenting: Love and Logic